Healthcare

Boston Scientific Stock (BSX): Solid Q1 Earnings Growth

Boston Scientific posts strong Q1 earnings, outperforming expectations with 20.9% growth. Diversification aids long-term prospects for investors.

Herbalife Rally Faces Test with Earnings Ahead

Herbalife stock up ahead of its upcoming earnings release, fueled by improved credit ratings and debt reduction—but volatility still clouds the outlook.

Northwest Biotherapeutics Stock (NWBO) Faces Challenges Ahead

Northwest Biotherapeutics (NWBO stock) bounces in pre-market trading after a steep drop, as investors reassess its high-stakes outlook amid mounting volatility.

Hims & Hers Health (HIMS): Growth Amid Regulatory Challenges

Hims & Hers saw strong revenue growth but faces margin pressure and new FDA rules on weight-loss drugs. Can it adapt? Here’s what retail investors need to know.

Illumina Inc. (ILMN): Navigating Trade Restrictions Amid Rising Competition

China's ban on Illumina’s gene-sequencing machines escalates trade tensions, opening market share to domestic rivals. Investors should watch for biotech volatility.

Walgreens Boots Alliance Inc. (WBA): Upcoming Acquisition by Sycamore Partners

Sycamore Partners nears a $10B Walgreens buyout, potentially breaking up the retail giant. What it means for investors, market dynamics, and strategic shifts.

FAQs on Medicus Pharma's Interim Data Update - 6 March 2025

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a novel skin cancer treatment. Here are FAQs explaining this breakthrough.

Interim Data Update from Medicus Pharma’s Phase 2 Clinical Trial

Medicus Pharma reports a positive trend in its interim Phase 2 trial analysis for a revolutionary skin cancer treatment. Key details on this major breakthrough.

2Seventy Bio (TSVT): Surge Following Acquisition Announcement

2Seventy Bio jumps 77% as Bristol Myers Squibb announces a $5-per-share buyout. Learn how this deal reshapes biotech investing and what it means for you.

Gilead Sciences (GILD): Potential Impact of Federal HIV Funding Cuts

Gilead Sciences shares fall amid reports of potential federal funding cuts for HIV initiatives, raising concerns for investors.

Haleon (HLN): Pfizer Sells Stake in Consumer Healthcare Firm

Pfizer has finalized its exit from Haleon by selling its remaining stake for £2.5 billion, marking a significant milestone for the firm.

23andMe (NASDAQ: ME): Bankruptcy Filing and Strategic Sale Process

23andMe has filed for Chapter 11 to maximize business value while facing a steep decline, leadership change, and investment risks surrounding genetics.

Eli Lilly and Co (NYSE:LLY): Promising Breakthrough in Weight-Loss Treatments

Eli Lilly's orforglipron shows promise as a weight-loss pill, boosting shares by 12% and marking a major milestone in diabetes treatment.

Roche (RHHBY): Significant U.S. Investment to Enhance Manufacturing and Innovation

Roche plans to invest $50 billion in the U.S., creating over 12,000 jobs and expanding its manufacturing and R&D capabilities.

How to Invest in Medicus Pharma

Medicus Pharma (MDCX) is developing a breakthrough skin cancer patch targeting a $15B+ market. Strong IP, Phase 2 progress - learn how to invest.